Episode
Eylea HD Approved for RVO and Extended Dosing
- Podcast
- Eyewire News: The Podcast
- Published
- Dec 3, 2025
- Duration seconds
- 300
- Processing state
not_requested- Canonical source
- https://traffic.megaphone.fm/BMCL2530398360.mp3
Actions
POST https://stenobird.com/v1/public/podcasts/eyewire-news-the-podcast-7055536/episodes/eylea-hd-approved-for-rvo-and-extended-dosing/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/eyewire-news-the-podcast-7055536/eylea-hd-approved-for-rvo-and-extended-dosing.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Eylea HD gains FDA approval for a new indication and dosing schedule; Lucentis biosimilar Byooviz receives a key approval in Europe; and Belite Bio announces topline results from its global phase 3 trial evaluating its drug candidate for Stargardt disease. Learn more about your ad choices. Visit megaphone.fm/adchoices